# CSMD3

Source: https://onco.cc/targets/csmd3/  
OnCo record `csmd3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CSMD3 (CUB and sushi domain-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 5 more.

## Summary

Involved in dendrite development.

Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.42, genetic association 0.51, somatic mutation 0.76). IntOGen calls it a driver in 46 cohorts (26 activating, 19 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Glioblastoma Multiforme and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: CUB and Sushi multiple domains 3; CUB and sushi domain-containing protein 3
- Tags: cancer-genes-wave
- Symbol: CSMD3
- Class: oncogene
- Biology: Involved in dendrite development. Location: Cell membrane (UniProt). Locus 8q23.3 (HGNC).
- Where found: Prostate cancer: IntOGen driver in 9 cohorts (PRAD); Hepatocellular carcinoma: IntOGen driver in 4 cohorts (HCC); Head and neck squamous cell carcinoma: IntOGen driver in 4 cohorts (HNSC); Gastric & gastro-oesophageal junction cancer: IntOGen driver in 4 cohorts (STAD); Breast cancer: IntOGen driver in 3 cohorts (BRCA); Colorectal cancer: IntOGen driver in 3 cohorts (COAD, COADREAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 26 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 19 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:19291: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19291
- UniProt Q7Z407: https://www.uniprot.org/uniprotkb/Q7Z407/entry
- NCBI Gene 114788: https://www.ncbi.nlm.nih.gov/gene/114788
- Ensembl ENSG00000164796: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164796

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/csmd3.json